Bildkälla: Stockfoto

Redwood Pharma: Clear Focus on Increased Shareholder Value - Analysguiden

As expected, Redwood Pharma reported no sales during Q1, and the operating result was SEK -4.3 million. Analysguiden reiterate their SEK 14 target pricce.

With positive clinical results, we see great potential in the company's share price. We assume that a launch of RP101 will take place in 2025, and that the drug will reach sales of EUR 500 million. We reiterate our target price of SEK 14 for Redwood Pharma. In our bull scenario, we see the potential for a value of SEK 28 per share, and in our more pessimistic bear scenario, the corresponding figure is SEK 7 per share.
Börsvärldens nyhetsbrev
ANNONSER